Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J. van den Bent, Johan M. Kros, Brigitta G. Baumert et al.|The Lancet|2017Cited by 401
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J. van den Bent, Brigitta G. Baumert, C. Mircea S. Tesileanu et al.|The Lancet Oncology|2021Cited by 333
Results of a phase II trial of the GliaSite Radiation Therapy System for the treatment of newly diagnosed, resected single brain metastasesLisa R. Rogers, Edward G. Shaw, Judith S. Billingsley et al.|Journal of neurosurgery|2006Cited by 102
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC. Mircea S. Tesileanu, Pim J. French, Martin J. van den Bent et al.|Neuro-Oncology|2021Cited by 66
Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.Martin J. van den Bent, Sara Erridge, Michael A. Vogelbaum et al.|Journal of Clinical Oncology|2025Cited by 5